{"id":36665,"date":"2026-02-21T15:34:49","date_gmt":"2026-02-21T20:34:49","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=36665"},"modified":"2026-02-22T17:38:14","modified_gmt":"2026-02-22T22:38:14","slug":"the-margin-machine-how-branded-generics-print-20-returns-on-drugs-anyone-can-make","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-margin-machine-how-branded-generics-print-20-returns-on-drugs-anyone-can-make\/","title":{"rendered":"The Margin Machine: How Branded Generics Print 20%+ Returns on Drugs Anyone Can Make"},"content":{"rendered":"\n

An investigative analysis of the business architecture behind pharma’s most durable profit model<\/em><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

When Pfizer’s patent on atorvastatin expired in 2011, every analyst on Wall Street braced for the same story: a 90% price collapse, mass switching to generics, and the rapid commoditization of a $13 billion-a-year drug. In the United States, that story played out almost exactly as predicted. Within 12 months, generic atorvastatin captured more than 80% of prescriptions, and the price per pill dropped from roughly $5.50 to under $0.15.<\/p>\n\n\n\n

But in Brazil, India, Egypt, and dozens of other markets, something different happened. Pfizer kept selling atorvastatin under the Lipitor brand at prices four to six times above generic equivalents. Physicians kept prescribing it. Patients kept paying for it. And Pfizer kept reporting operating margins on the product that, by most conservative estimates, stayed north of 25%.<\/p>\n\n\n\n

That gap between what the economics textbooks predict and what actually happens in pharma markets is the branded generic story. It is a business model that should not, by any rational measure, work as well as it does. Yet companies like Sun Pharmaceutical, Abbott India, Servier, Viatris, and a dozen others have built entire enterprise architectures around maintaining price premiums on molecules that any competent manufacturer can produce for pennies.<\/p>\n\n\n\n

This analysis maps exactly how they do it, why the margins hold, where the model is most vulnerable, and what the patent data actually tells you when you dig into the numbers.<\/p>\n\n\n\n

What a Branded Generic Actually Is<\/h2>\n\n\n\n

The pharmaceutical industry uses the term loosely, which creates analytical confusion. A branded generic is, at its core, a drug product that contains an off-patent active pharmaceutical ingredient but is sold under a proprietary brand name, usually by the original innovator or by a company that has licensed the brand. It is not a new chemical entity. It carries no primary patent protection on the molecule itself. Any manufacturer with the right equipment and regulatory clearance can make the same active ingredient.<\/p>\n\n\n\n

What distinguishes it from a plain generic is not the chemistry. It is the commercial infrastructure built around the product: the brand name, the physician relationships, the packaging, the marketing spend, the distribution agreements, and sometimes (though not always) secondary intellectual property around formulation, delivery mechanism, or dosage form.<\/p>\n\n\n\n

The Product Spectrum<\/h3>\n\n\n\n

Think of the market as a four-point spectrum rather than a binary. At one end sits the originator brand, still on patent, with full pricing power and regulatory exclusivity protecting it. One step down is the authorized generic, launched by the innovator itself through a separate legal entity to compete with its own product during the patent cliff. Then comes the branded generic proper, a post-patent product sold under a proprietary name by the originator or a licensing partner. At the far end is the unbranded generic, a commodity product sold purely on price.<\/p>\n\n\n\n

Most analysis focuses on the extremes. The branded generic sits in a commercially rich middle ground that gets relatively little attention, partly because it does not generate the dramatic patent cliff headlines of innovator drugs, and partly because the margin drivers are subtle enough that they require patient investigation to understand.<\/p>\n\n\n\n

Why the Distinction Matters for Investors and Analysts<\/h3>\n\n\n\n

From a portfolio analysis perspective, branded generics behave differently from both innovator drugs and commodity generics on almost every relevant dimension: margin trajectory, revenue predictability, competitive response curves, and capital intensity. A pharma investor who models branded generic revenue using either innovator assumptions or commodity generic assumptions will be wrong in both cases, usually materially so.<\/p>\n\n\n\n

Operating margins on true branded generics in established markets typically run between 18% and 32%, compared to 4% to 12% for unbranded generics and 35% to 55% for still-on-patent innovator drugs. The branded generic carves out a durable middle band. Understanding why that band exists and how sustainable it is requires looking at five specific economic mechanisms working in concert.<\/p>\n\n\n\n

The Patent Cliff Does Not Kill All Margins: Here is Why<\/h2>\n\n\n\n

The standard patent cliff model assumes that generic entry triggers immediate and severe price erosion because pharmaceutical markets behave like commodity markets. That assumption holds reasonably well in the United States, where pharmacy benefit managers, insurance formularies, and automatic substitution laws create intense structural pressure toward the cheapest bioequivalent. It does not hold uniformly elsewhere, and even in the United States it holds less completely than the textbooks suggest.<\/p>\n\n\n\n

Where the Model Breaks<\/h3>\n\n\n\n

The commodity model requires several conditions to produce full price erosion: transparent pricing, rational switching behavior by both prescribers and patients, absence of brand loyalty, and no significant differentiation between products. In many pharmaceutical markets, at least two of those four conditions fail to hold.<\/p>\n\n\n\n

Physician prescribing behavior is the first place the model breaks. Multiple studies across therapeutic categories have found that once a physician has prescribed a drug under a brand name and observed outcomes, they exhibit significant inertia. A 2019 study published in the Journal of Health Economics analyzing prescribing patterns across 14 European markets found that physicians who had prescribed the originator drug for more than 24 months switched to an unbranded generic at roughly half the rate of physicians who had adopted the drug more recently. Brand familiarity functions as a mental shortcut in a cognitive environment where physicians are evaluating dozens of patients and hundreds of drug options simultaneously.<\/p>\n\n\n\n

Patient behavior is the second failure point. In markets where patients pay a meaningful share of drug costs directly, willingness to pay a premium for a recognized brand name tracks closely with disease severity and treatment duration. A patient managing chronic hypertension for ten years with a familiar pill does not want to switch. The behavioral switching cost is real even when the pharmacological difference is zero.<\/p>\n\n\n\n

The Margin Architecture After Patent Expiration<\/h3>\n\n\n\n

What remains after patent expiration is not nothing. The innovator retains the brand trademark. It retains physician relationships built over years of medical education, sponsored trials, and sales force contact. It retains the formulation know-how, even if competitors can develop their own. And in many markets, it retains a regulatory head start because drug approval is not instantaneous.<\/p>\n\n\n\n

These retained assets do not maintain a 100% price premium. They typically maintain a 15% to 40% premium over the cheapest generic in the market. That is enough, when combined with manufacturing scale and reduced marketing spend (since you no longer need to build awareness), to generate operating margins that exceed what most unbranded generic manufacturers can dream of.<\/p>\n\n\n\n

“In emerging markets, the branded generic segment commands an average price premium of 28% over unbranded equivalents, while incurring 60-70% lower promotional expenditure than the equivalent innovator product in its primary patent period.”<\/em> \u2014 IQVIA Branded Generics Market Report, 2024<\/p>\n\n\n\n

Five Levers That Sustain 20%+ Operating Margins<\/h2>\n\n\n\n

No single mechanism explains the margin durability of branded generics. It is a combination of five reinforcing factors, each contributing differently depending on the therapeutic category, the geography, and the company’s specific market position.<\/p>\n\n\n\n

Lever 1: Brand Equity as a Pricing Floor<\/h3>\n\n\n\n

Brand equity in pharmaceuticals is not the same as brand equity in consumer goods, though the economic structure is similar. In consumer goods, brand equity reflects consumer preference driven by taste, aspiration, or habit. In pharmaceuticals, it reflects physician confidence, patient familiarity, and institutional inertia in procurement decisions.<\/p>\n\n\n\n

The practical manifestation is a pricing floor. A physician who has prescribed Lipitor (atorvastatin) for fifteen years to a stable patient population will not automatically switch those patients to a generic equivalent simply because one becomes available. The physician’s default is to maintain the prescription unless there is active pressure to change it. That pressure comes primarily from payer formulary rules in the United States, but in markets with weaker payer consolidation, it is far less intense.<\/p>\n\n\n\n

How the Price Anchor Works<\/h4>\n\n\n\n

Branded generics typically price between 15% and 40% below the originator drug’s peak price in the market, but 20% to 60% above the cheapest generic. This creates a positioning that captures two sources of value simultaneously: it appears discounted to patients and physicians comparing it against the innovator price, while appearing premium against the generic shelf.<\/p>\n\n\n\n

The anchor to the innovator price is critical. When Pfizer’s Norvasc (amlodipine besylate) went off patent, Pfizer continued selling Norvasc at a price only marginally below the pre-expiry level in several Asian markets. The existence of that branded price point provided the psychological reference against which physicians evaluated the unbranded generic. A patient who had been paying the equivalent of $45 for Norvasc was often willing to continue paying $30 rather than switching to a $6 generic, particularly when their physician prescribed by brand name.<\/p>\n\n\n\n

Physician Loyalty Programs and Medical Education<\/h4>\n\n\n\n

The commercial mechanisms maintaining brand equity do not disappear at patent expiration. They get reallocated. A branded generic manufacturer typically reduces its primary sales force after the patent cliff, but maintains a lighter-touch engagement model: continuing medical education programs, pharmacovigilance data sharing, disease awareness campaigns, and key opinion leader relationships. These activities cost significantly less than the full promotional spend required during a drug’s primary patent period, but they keep the brand visible and credible.<\/p>\n\n\n\n

Abbott India’s strategy in its branded generics portfolio provides a useful illustration. The company maintains a field force of roughly 5,000 medical representatives across India, who call on approximately 80,000 physicians. That ratio (one representative for every 16 physicians) is lower than typical innovator standards, but high enough to maintain prescribing relationships. The result is that Abbott India commands price premiums of 25% to 45% in categories including anti-infectives, gastrointestinal drugs, and metabolic medicines, even where multiple generic competitors exist.<\/p>\n\n\n\n

Lever 2: Formulation Differentiation and Secondary IP<\/h3>\n\n\n\n

When the primary patent on a molecule expires, the molecule itself becomes a commodity. But the formulation surrounding it need not be. Extended-release technologies, novel drug delivery systems, improved bioavailability profiles, and reformulated dosage forms can all attract their own intellectual property protection, typically through formulation patents, process patents, or regulatory data exclusivity.<\/p>\n\n\n\n

The pharmaceutical industry calls this strategy ever-greening when practiced by innovators. In the branded generic context, the same logic applies to companies that develop improved versions of off-patent molecules. These are not cynical extensions of expired patents but genuine reformulations that sometimes offer real clinical benefits, and sometimes offer primarily commercial ones.<\/p>\n\n\n\n

Extended-Release as a Margin Strategy<\/h4>\n\n\n\n

Extended-release formulations illustrate the pattern clearly. Metformin, the first-line treatment for type 2 diabetes, came off patent decades ago. The immediate-release version is now one of the cheapest drugs in the world. But extended-release metformin, which reduces gastrointestinal side effects and enables once-daily dosing, carries formulation patents that vary by jurisdiction. Companies that developed or licensed ER metformin technologies maintained price premiums of 3x to 8x over immediate-release generics in multiple markets through the 2010s and into the 2020s.<\/p>\n\n\n\n

The margin arithmetic on a well-positioned ER formulation is attractive. The active ingredient cost is essentially the same as the immediate-release version. The additional manufacturing complexity adds perhaps 15% to 25% to production cost. But the price premium can be 200% to 400%. Net margin expands substantially even before accounting for lower sales force requirements due to the genuine clinical differentiation.<\/p>\n\n\n\n

Using Patent Databases to Map the IP Landscape<\/h4>\n\n\n\n

Identifying which formulation patents apply to a given compound in a given market, and when they expire, is one of the most commercially valuable exercises in pharmaceutical competitive intelligence. DrugPatentWatch, a platform that aggregates patent data from multiple regulatory and intellectual property databases, allows analysts to query patent status, expiry dates, and pending challenges for drugs in the US market and across multiple international jurisdictions.<\/p>\n\n\n\n

Practically speaking, a competitor analysis of a branded generic market position starts with the patent landscape. If a branded generic holds only the trademark and no formulation IP, the competitive moat is purely behavioral and therefore more fragile. If it holds formulation patents expiring in three to seven years, the margin premium is defensible over a medium-term investment horizon. The distinction matters enormously for both competitive strategy and valuation.<\/p>\n\n\n\n

Lever 3: Distribution Infrastructure and Market Access<\/h3>\n\n\n\n

In markets with fragmented retail pharmaceutical distribution, the ability to guarantee product availability, consistent supply, and reliable cold-chain management is not a trivial operational capability. It is a genuine competitive advantage that translates directly into prescribing behavior and margin preservation.<\/p>\n\n\n\n

The Emerging Market Distribution Moat<\/h4>\n\n\n\n

India’s pharmaceutical distribution system illustrates the dynamic clearly. The country has approximately 800,000 retail pharmacies, served by roughly 65,000 stockists, who are in turn served by around 3,000 clearing-and-forwarding agents. In this system, a drug that is not consistently available at the pharmacy level loses prescriptions not because physicians choose to switch but because the pharmacy recommends an alternative when the branded product is out of stock.<\/p>\n\n\n\n

Companies with large distribution footprints that ensure consistent shelf presence maintain a structural advantage that new entrants or smaller competitors cannot easily replicate. Sun Pharma’s domestic India business and Cipla’s branded generic operations both rest on distribution networks built over decades, comprising thousands of distributor relationships, that effectively guarantee pharmacy penetration across tier-1, tier-2, and tier-3 cities.<\/p>\n\n\n\n

The margin implication is direct. A drug with 95% pharmacy availability commands a price premium over a drug with 70% availability, because the prescribing physician knows the patient will actually be able to fill the prescription. Distribution reliability is part of what the price premium pays for.<\/p>\n\n\n\n

Channel Control and the Pharmacy Relationship<\/h4>\n\n\n\n

In markets where pharmacists have significant latitude to recommend or substitute products (which describes most emerging markets), the branded generic company’s relationship with the pharmacist is a margin lever of its own. Pharmacy margin programs, training initiatives, and loyalty structures are common commercial tools. They are also, in many markets, matters of ongoing regulatory scrutiny.<\/p>\n\n\n\n

The legitimate version of the pharmacy relationship model is straightforward: branded generic companies offer pharmacists faster payment terms, better return policies, and marketing support materials compared to unbranded generics, which compete purely on price. A pharmacist running a small retail operation places real economic value on reliability, support, and the ability to answer patient questions confidently. These factors provide the branded generic with margin room the unbranded competitor cannot access.<\/p>\n\n\n\n

Lever 4: Manufacturing Scale and Vertical Integration<\/h3>\n\n\n\n

The manufacturing economics of branded generics are frequently misunderstood. The common assumption is that because the active ingredient is off-patent, the commodity cost is the same for everyone. That is true for the molecule itself, but the total cost of goods sold depends on API sourcing, formulation capabilities, manufacturing scale, and quality systems. Companies with vertically integrated manufacturing operations, their own API synthesis, and large-scale finished product manufacturing carry a meaningful cost advantage over smaller competitors.<\/p>\n\n\n\n

API Backward Integration<\/h4>\n\n\n\n

Active pharmaceutical ingredient production is capital-intensive but scale-sensitive. A company producing 500 metric tons of atorvastatin API per year carries a fundamentally different cost structure than one producing 5 metric tons. The large-scale producer can sell branded generics at a premium price while simultaneously maintaining cost-of-goods below the manufacturing cost of the commodity generic producer who sources API externally.<\/p>\n\n\n\n

India’s pharmaceutical sector built its branded generic economics partly on this foundation. Companies like Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories invested in API manufacturing capacity through the 1990s and 2000s that gave them cost structures inaccessible to competitors. When those companies sell branded generics at premium prices in domestic and emerging markets, they are extracting margin from two directions: a revenue premium from the brand, and a cost advantage from manufacturing scale.<\/p>\n\n\n\n

The Quality Premium Is Real<\/h4>\n\n\n\n

One factor that industry observers sometimes dismiss as marketing is the quality differential between branded and unbranded generic products in markets with limited regulatory oversight. In markets where good manufacturing practice (GMP) enforcement is inconsistent, the actual quality of unbranded generics can vary significantly from the branded equivalent. Dissolution rates, bioavailability, and stability specifications are enforced rigorously in markets like the United States and European Union, but less systematically in parts of Southeast Asia, Africa, and Latin America.<\/p>\n\n\n\n

In these markets, a physician’s preference for a branded generic is not pure irrationality. It reflects a rational inference about manufacturing quality that is difficult to verify independently. Companies with internationally audited manufacturing plants (WHO prequalification, US FDA approval, or EU Good Manufacturing Practice certification) can credibly signal quality that supports the price premium.<\/p>\n\n\n\n

Lever 5: Regulatory Arbitrage and Data Exclusivity<\/h3>\n\n\n\n

The regulatory dimension of branded generic margin maintenance operates differently across markets. In markets with strong generic substitution laws and automatic bioequivalence frameworks, regulatory advantages are minimal. In markets where drug registration is slow, complex, or underdeveloped, the existing approved product holds a registration advantage that can last years after patent expiration.<\/p>\n\n\n\n

Registration as a Market Entry Barrier<\/h4>\n\n\n\n

Getting a generic drug approved is not free or instantaneous. In markets with limited regulatory capacity, registration of a new generic can take three to five years. During that window, the branded generic faces no price competition even if the primary patent has expired, because there is no approved alternative. The regulatory timeline creates an artificial exclusivity that supports premium pricing without requiring any intellectual property.<\/p>\n\n\n\n

This is particularly relevant in sub-Saharan African markets, where regulatory agencies in many countries have limited capacity to process and approve generic applications. A branded generic registered before patent expiry can maintain its market position for years after the primary patent has lapsed simply because no approved generic alternative yet exists in the regulatory system.<\/p>\n\n\n\n

Data Exclusivity and the Registration Data Package<\/h4>\n\n\n\n

Even in markets with faster regulatory processing, data exclusivity rules provide a separate layer of protection. Data exclusivity prevents generic manufacturers from relying on the innovator’s clinical trial data for a set period, requiring them either to conduct their own trials or wait for the exclusivity window to close. In the United States, the Hatch-Waxman Act provides five years of data exclusivity for new chemical entities and three years for new clinical investigations of approved drugs.<\/p>\n\n\n\n

The commercial implication is that even a branded generic company that is not the original innovator but has performed new clinical work on a known molecule can claim its own data exclusivity period. Companies that invest in new indication studies, new patient population data, or new formulation clinical trials for off-patent molecules generate exclusivity protection that delays generic competition even when the molecule itself is freely copyable.<\/p>\n\n\n\n

Case Studies: Companies That Have Mastered the Model<\/h2>\n\n\n\n

Abbott India: The Original Playbook<\/h3>\n\n\n\n

Abbott’s India operations, now operating as a separately listed entity, represent perhaps the most studied example of branded generic margin maintenance. The company’s Indian portfolio is almost entirely branded generics across cardiovascular, gastrointestinal, women’s health, and metabolic disease categories. Approximately 90% of its revenue comes from products where the active ingredient has been off-patent for at least a decade. Yet Abbott India has consistently reported operating margins between 22% and 27%, significantly above the Indian pharmaceutical industry average.<\/p>\n\n\n\n

The company’s strategy rests on three foundations: a large and highly trained medical sales force, aggressive brand maintenance through physician education programs, and product line extensions that add genuine clinical utility (such as combination products combining off-patent molecules in fixed-dose formulations that require their own regulatory filings and sometimes attract formulation IP).<\/p>\n\n\n\n

The combination product strategy deserves particular attention. Abbott India has been particularly active in developing fixed-dose combinations (FDCs) of two or three off-patent drugs in a single tablet, targeting conditions where polypharmacy is common and patient compliance is problematic. A fixed-dose combination of a calcium channel blocker and an ACE inhibitor for hypertension is clinically useful, commercially differentiated, and regulatory distinct from its component generics. Abbott registers and brands these combinations under proprietary names, achieving a price point substantially above what either component generic would command individually.<\/p>\n\n\n\n

Sun Pharma: Specialty and Branded Generic Convergence<\/h3>\n\n\n\n

Sun Pharmaceutical Industries built its initial business on branded generics in the Indian domestic market, then expanded internationally. Its domestic branded generic operations consistently generate operating margins in the 25% to 32% range, with particularly strong positions in psychiatry, dermatology, and cardiology. The company’s commercial approach emphasizes deep specialization by therapeutic area: its psychiatry sales force calls almost exclusively on psychiatrists and neurologists, building relationships that translate into prescribing habits resistant to generic substitution.<\/p>\n\n\n\n

Sun’s international expansion, particularly its acquisition of Ranbaxy in 2014 and subsequent development of specialty branded products for the US market, represents an evolution of the branded generic model toward specialty pharma. The company has developed branded generics with specific delivery innovations (such as extended-release formulations and novel topical delivery systems for dermatology) that command US price points substantially above commodity generics while requiring less regulatory investment than fully new chemical entities.<\/p>\n\n\n\n

Analysts tracking Sun Pharma through patent databases like DrugPatentWatch can trace its formulation patent filings, identify which products carry secondary IP protection, and model when competitive generic entry becomes structurally possible versus merely legally possible. The distinction matters: a competitor might be legally able to enter a market once a primary patent expires, but face a three-year data exclusivity period on a formulation patent, a two-year regulatory review queue, and an entrenched physician preference. The effective exclusivity period is far longer than the patent alone suggests.<\/p>\n\n\n\n

Pfizer’s Upjohn Division: The Pivot Strategy<\/h3>\n\n\n\n

Pfizer’s decision to create the Upjohn division (later spun off and merged with Mylan to form Viatris in 2020) represented an explicit acknowledgment that mature branded products can be managed as a distinct business with its own economic logic. Upjohn housed Pfizer’s portfolio of off-patent branded drugs, including Lipitor, Norvasc, Celebrex, and Viagra, and focused them primarily on emerging markets where brand equity remained commercially potent.<\/p>\n\n\n\n

The Upjohn thesis was that these brands, managed with a lower cost base than innovator drugs require, could sustain margins of 20% to 30% in markets where brand loyalty persisted. Pfizer’s internal data on price elasticity across markets showed that in China, Russia, Brazil, and Southeast Asia, physician and patient price sensitivity for established branded drugs was substantially lower than in the United States. A drug with 25 years of clinical history and strong brand recognition in emerging markets does not face the same commoditization pressure as an identical molecule launched by a generic company with no track record.<\/p>\n\n\n\n

The subsequent performance of Viatris since its 2020 formation has been more complicated, reflecting both the challenges of integrating two large organizations and the ongoing evolution of competitive dynamics in key emerging markets. The core branded generic thesis has held in some markets better than others, with China’s national volume-based procurement programs representing a significant headwind to premium pricing that Pfizer did not fully anticipate.<\/p>\n\n\n\n

Reading the Patent Data: What the Numbers Actually Tell You<\/h2>\n\n\n\n

Patent analysis is the most reliable starting point for assessing the competitive position of any branded generic product. But raw patent data requires interpretation. A patent expiry date tells you when primary protection ends. It does not tell you whether secondary patents exist, whether data exclusivity applies, how long regulatory review of a generic application will take in the target market, or whether the innovator has filed patent challenges that could delay generic entry.<\/p>\n\n\n\n

Primary Patents vs. the Full IP Stack<\/h3>\n\n\n\n

A thorough patent analysis of any drug product distinguishes between the primary patent (covering the molecule itself), formulation patents (covering specific dosage forms or delivery technologies), process patents (covering manufacturing methods), and combination patents (covering fixed-dose combinations with other agents). Each layer can provide additional market exclusivity beyond the primary patent expiration.<\/p>\n\n\n\n

For a branded generic manager, this IP stack analysis serves a different purpose than for a generic competitor. The generic company wants to find gaps in the IP stack to exploit. The branded generic manager wants to understand where the stack is thin and where it is defensible, because thin stack positions are where generic competition will arrive fastest and most aggressively.<\/p>\n\n\n\n

Using DrugPatentWatch for Competitive Intelligence<\/h3>\n\n\n\n

DrugPatentWatch aggregates US Orange Book patent listings, Paragraph IV certification data, patent litigation records, and exclusivity information into a searchable database that allows pharmaceutical analysts to assess the patent position of any approved drug product in the US market. For branded generic analysis, the platform is particularly useful for identifying paragraph IV challenges (which signal that a generic company has concluded the patent is invalid or non-infringed), the number of ANDA filers for a given product (which predicts the intensity of generic competition after approval), and any 180-day generic exclusivity awards (which create a temporary duopoly between the first generic entrant and the branded product).<\/p>\n\n\n\n

The 180-day exclusivity period created by Hatch-Waxman is a commercial detail that branded generic companies sometimes overlook but should not. During the 180 days in which only the first-approved generic can compete with the branded product, the price erosion is substantially less than it will be when additional generics enter. Companies that actively manage pricing strategy during this window, rather than simply maintaining the pre-expiry branded price, can extract significant additional margin before multi-source generic competition arrives.<\/p>\n\n\n\n

Paragraph IV Challenges as Early Warning Signals<\/h3>\n\n\n\n

When a generic manufacturer files an ANDA with a Paragraph IV certification (asserting that existing patents are invalid or will not be infringed), that filing is public information that becomes a competitive signal for the branded product holder. Typically, the innovator’s response to a Paragraph IV challenge is to file a patent infringement lawsuit, which triggers an automatic 30-month stay of FDA approval of the generic.<\/p>\n\n\n\n

For a branded generic company, Paragraph IV activity against its products provides a 30-month horizon within which to accelerate brand-building, deepen physician relationships, and potentially launch a formulation extension or authorized generic that will compete favorably with the generic entrant when it does arrive. Companies that track Paragraph IV filings systematically, using tools like DrugPatentWatch to monitor their competitive landscape, are substantially better prepared for generic entry than those who wait for the generic launch to respond.<\/p>\n\n\n\n

Pricing Strategy in the Branded Generic World<\/h2>\n\n\n\n

The Price Anchor Mechanism in Practice<\/h3>\n\n\n\n

Branded generic pricing does not operate in isolation. It operates in relationship to two reference points: the current branded price and the cheapest available generic. The branded generic typically needs to be below the branded price (or at parity in markets where it IS the branded product) and above the generic floor. The size of that spread determines the margin available.<\/p>\n\n\n\n

Companies set this spread by analyzing market-specific price sensitivity data, physician switching elasticity, and payer behavior. In markets where payer pressure is minimal (most private-pay emerging markets), the spread can be 40% to 60%. In markets with active payer negotiation but without automatic generic substitution, the spread typically runs 20% to 35%. In markets with formulary-driven substitution, it compresses toward 10% to 20% or eventually disappears.<\/p>\n\n\n\n

The Trust Premium: What Buyers Are Actually Paying For<\/h3>\n\n\n\n

When a physician prescribes a branded generic at a 30% premium over an identical generic, and a patient fills that prescription willingly, what exactly is being purchased? The chemistry is the same. The regulatory approval standard is the same (bioequivalence). What differs is a bundle of attributes that economists call credence goods: qualities that are difficult or impossible to verify at the point of purchase.<\/p>\n\n\n\n

Manufacturing quality consistency is the primary credence attribute. A branded product from a company with an internationally audited manufacturing facility, a published pharmacovigilance record, and a history of consistent supply provides verified quality signals that an unbranded generic from an opaque manufacturer does not. This is not pure marketing. In markets with inconsistent GMP enforcement, the trust premium reflects real information asymmetry.<\/p>\n\n\n\n

Customer service infrastructure is the secondary attribute. A branded generic company typically provides a medical information hotline, adverse event reporting systems, and field-based support that the generic equivalent does not. For hospital procurement, these support services carry genuine institutional value.<\/p>\n\n\n\n

The practical implication for margin sustainability is important: trust premiums are most durable in markets where the quality differential is credible and the information asymmetry is genuine. As markets develop more robust generic approval frameworks and enforce GMP standards more consistently, the trust premium erodes and the pricing floor descends.<\/p>\n\n\n\n

Price Defense Strategies at the Patent Cliff<\/h3>\n\n\n\n

Companies that fail to plan for patent expiry typically experience the worst margin outcomes. Those that actively manage the transition maintain margins substantially better. The most effective price defense strategies involve four elements working together rather than treating any single tactic as sufficient.<\/p>\n\n\n\n

First, authorized generic programs allow the innovator to compete in the generic segment directly, capturing volume even as branded price erodes. Second, combination product launches that pair the expiring drug with a companion molecule extend the commercial life of the formulation in a new IP wrapper. Third, strategic reformulation, moving from immediate-release to extended-release or from tablet to a preferred delivery format, creates differentiation that slows automatic switching. Fourth, price tiering, explicitly targeting different price points at different market segments (hospital versus retail, private versus public), allows capture of premium segments while conceding price-sensitive segments without universal price decline.<\/p>\n\n\n\n

Where the Model Faces Real Pressure<\/h2>\n\n\n\n

China’s Volume-Based Procurement: A Genuine Structural Risk<\/h3>\n\n\n\n

The most significant systemic threat to branded generic margins in recent years has come not from the traditional patent cliff but from China’s national volume-based procurement (VBP) program, which began in 2019 and has expanded aggressively since. The VBP program uses centralized government tendering to drive drug prices down by 50% to 95% from pre-tender levels in exchange for guaranteed volume across national health insurance hospitals.<\/p>\n\n\n\n

For companies that had built branded generic businesses in China on the assumption that physician loyalty would protect price premiums, VBP has been a decisive disruption. When a government tender requires hospitals to switch to the lowest-cost tender winner, physician preference becomes legally and institutionally irrelevant. The brand cannot overcome a procurement mandate.<\/p>\n\n\n\n

Pfizer’s Upjohn division reported China VBP as a primary factor in revenue decline across multiple key products. Novartis, AstraZeneca, and several Japanese pharmaceutical companies with significant China branded generic businesses have faced similar pressure. The China VBP experience is now a reference case for what happens when a market mechanism is specifically designed to eliminate the competitive advantages that sustain branded generic premiums.<\/p>\n\n\n\n

Generic Substitution Laws and Pharmacist Authority<\/h3>\n\n\n\n

Legislative changes granting pharmacists authority to substitute generics at the pharmacy counter without physician approval represent the single policy change most corrosive to branded generic market position. Countries that have implemented mandatory generic substitution policies, including several European Union member states, Australia, and Canada, have seen branded generic price premiums compress dramatically within two to three years of implementation.<\/p>\n\n\n\n

The key variable is whether substitution is mandatory or merely permitted. In markets where pharmacists may substitute but are not required to, substitution rates remain moderate and branded generics retain meaningful share. When substitution is mandatory (the pharmacist must dispense the cheapest bioequivalent unless the physician specifically indicates brand-necessary), the branded generic business model collapses toward commodity economics within a short time.<\/p>\n\n\n\n

Regulatory trend monitoring is consequently a core responsibility for branded generic business managers. The policy trajectory in a given market often provides two to four years of advance notice before mandatory substitution is implemented, which is sufficient time to reposition the business toward formulation differentiation, combination products, or market expansion that is less policy-sensitive.<\/p>\n\n\n\n

Quality Scandals and the Trust Premium Collapse<\/h3>\n\n\n\n

The trust premium that supports branded generic pricing is fragile in one specific way: a quality failure at the manufacturing level can destroy it rapidly and permanently. The ransartan contamination crisis of 2018 and 2019, which affected multiple manufacturers producing valsartan, irbesartan, and losartan and led to widespread product recalls across dozens of markets, illustrates the risk.<\/p>\n\n\n\n

Companies whose products were recalled faced not just the immediate revenue loss from the recall but a sustained erosion of physician and patient confidence that lasted 18 to 36 months even after product quality was restored. The trust premium on which their branded pricing rested was the first casualty. Rebuilding that premium required significant additional investment in quality communication, physician outreach, and sometimes third-party quality auditing programs.<\/p>\n\n\n\n

Quality system investment is therefore not merely a regulatory compliance cost for branded generic companies. It is a brand protection cost, and it belongs in the economic model alongside sales force spend and marketing expenses.<\/p>\n\n\n\n

The Emerging Markets Opportunity: Where the Model Still Has Room to Run<\/h2>\n\n\n\n

India: The World’s Largest Branded Generic Market<\/h3>\n\n\n\n

India’s pharmaceutical market is structurally unusual in that branded generics are the dominant form of pharmaceutical marketing, rather than the exception. Unlike the United States, where branded drugs and unbranded generics are the primary categories, India’s market consists predominantly of branded generics: off-patent molecules sold under proprietary brand names by hundreds of domestic pharmaceutical companies.<\/p>\n\n\n\n

The Indian pharma market was valued at approximately $22 billion at the manufacturer level in 2024, with branded generics accounting for an estimated 70% of value. The market’s branded generic character reflects several historical and structural factors: a medical education system that trains physicians to prescribe by brand name, a fragmented retail pharmacy sector with limited capacity for automatic substitution, and a tradition of physician sampling and detailing as the primary commercial mechanism.<\/p>\n\n\n\n

For domestic companies like Sun Pharma, Cipla, Dr. Reddy’s, Lupin, and Abbott India, the branded generic model has generated consistent double-digit operating margins across economic cycles. The domestic Indian operations of these companies typically earn 20% to 30% EBITDA margins, funded by the combination of brand premiums and manufacturing cost advantages. Price controls exist for certain essential medicines through the National List of Essential Medicines and NPPA (National Pharmaceutical Pricing Authority) regulations, but cover only a portion of the market, leaving significant pricing freedom in non-essential categories.<\/p>\n\n\n\n

Sub-Saharan Africa: High Growth, High Risk<\/h3>\n\n\n\n

Sub-Saharan Africa represents one of the highest-growth regions for branded generics globally, with pharmaceutical market growth rates in several major economies (Nigeria, Kenya, Ethiopia, Ghana) running at 8% to 12% annually in real terms. The branded generic opportunity rests on several factors: rapidly growing middle-class populations with increasing healthcare expenditure, regulatory systems where brand registration provides durable competitive advantage, and physician prescribing cultures that favor recognized brand names.<\/p>\n\n\n\n

The risk profile is equally distinctive. Currency volatility, local manufacturing content requirements in several markets, regulatory unpredictability, and limited healthcare infrastructure constrain margin realization. Companies operating branded generics in sub-Saharan Africa typically target gross margins of 50% to 65%, but realization at the operating level is often 15% to 22% after accounting for distribution costs, regulatory compliance expenses, and currency hedging.<\/p>\n\n\n\n

The most successful operators in the region, including Aspen Pharmacare (South Africa), Strides Pharma, and Sanofi’s consumer health division, have built regional manufacturing capacity that reduces import dependency and currency exposure while supporting the quality credibility necessary to maintain brand premiums.<\/p>\n\n\n\n

Latin America: The Branded Generic Middle Ground<\/h3>\n\n\n\n

Latin America presents a more mature branded generic opportunity than Africa but a more dynamic one than Western Europe. Countries including Brazil, Mexico, Colombia, Chile, and Argentina have significant branded generic markets where regulatory frameworks are robust enough to protect quality but not so payer-dominated as to eliminate price premiums.<\/p>\n\n\n\n

Brazil’s pharmaceutical market is instructive. Generic substitution is legally permitted and pharmacists can substitute, but it is not mandatory, and physician prescribing by brand name remains common. As a result, branded generics maintain price premiums of 20% to 45% over unbranded equivalents across most categories. Companies including EMS, Eurofarma, Hypera, and the Brazilian operations of Sanofi, Pfizer, and Bayer have built profitable branded generic franchises on this foundation.<\/p>\n\n\n\n

The Brazilian market is also notable for the sophistication of its anti-counterfeit and track-and-trace infrastructure, which supports the quality credibility of established branded generics relative to products of uncertain provenance.<\/p>\n\n\n\n

The Investor’s View: Valuing Branded Generic Businesses<\/h2>\n\n\n\n

How the Market Prices Branded Generic Cash Flows<\/h3>\n\n\n\n

Branded generic businesses trade at valuation multiples that reflect their margin durability and growth profile, generally occupying a range between commodity generic multiples and innovator pharma multiples. A pure-play branded generic company in a favorable market (India, Southeast Asia, or Latin America) with demonstrated 20%+ operating margins and consistent revenue growth typically trades at 15x to 25x EBITDA. This compares to 7x to 12x for commodity generic companies and 18x to 30x for specialty innovator pharma.<\/p>\n\n\n\n

The key valuation driver beyond current margins is the sustainability of the price premium, which requires assessing the patent landscape, the regulatory environment, the quality of the sales force infrastructure, and the competitive intensity. Analysts who can assess these factors with precision have a genuine information advantage in valuing pharma companies where branded generics constitute a significant portion of revenue.<\/p>\n\n\n\n

Margin Trajectory Models<\/h3>\n\n\n\n

A branded generic revenue stream does not decline as sharply as a pure innovator drug post-patent cliff, but it does decline over a multi-year horizon as generic competition intensifies and price sensitivity increases. A well-constructed valuation model accounts for this through a graduated price erosion assumption rather than a step-function cliff.<\/p>\n\n\n\n

A reasonable base-case framework for a branded generic product in an emerging market: maintain price premium above commodity generic at 30% to 40% in years one through three post-generic entry, compressing to 20% to 25% in years four through six, and 10% to 15% in years seven through ten, after which the product is effectively a price-competitive branded generic fighting on distribution and physician relationships alone. Under this trajectory, operating margins compress from 25%+ in the primary period to 15% to 18% at the seven-to-ten-year mark, but do not collapse to commodity levels.<\/p>\n\n\n\n

Companies that execute effectively on formulation line extensions, combination products, and market expansion can arrest this compression, effectively resetting the price premium clock on specific products while the overall portfolio continues generating above-commodity margins.<\/p>\n\n\n\n

Red Flags in Branded Generic Financial Reporting<\/h3>\n\n\n\n

Investors analyzing branded generic companies should watch for specific signals of margin pressure that often precede reported results by two to four quarters. Gross margin compression before operating leverage appears is typically the first indicator that price premiums are eroding faster than anticipated. A reduction in the medical representative-to-physician ratio (often disclosed in annual reports for Indian pharma companies) signals reduced investment in relationship maintenance and typically precedes volume share loss.<\/p>\n\n\n\n

A significant increase in trade receivable days, particularly in markets with fragmented distribution, can signal that distributors are requiring longer credit terms because they face price competition at the retail level, which is a leading indicator of price erosion in the channel. These operational signals often precede the headline revenue and margin figures by a quarter or two, which creates useful analytical windows for informed investors.<\/p>\n\n\n\n

The Regulatory and Policy Landscape for the Next Five Years<\/h2>\n\n\n\n

Branded generic businesses do not operate in a static regulatory environment. The trajectory of healthcare policy globally is generally toward greater price transparency, stronger generic promotion, and increasing payer sophistication. Companies that build branded generic strategies without factoring in the regulatory direction of their target markets are building on a foundation that will shift.<\/p>\n\n\n\n

India’s Prescription Regulation Evolution<\/h3>\n\n\n\n

India’s Drug Technical Advisory Board and Ministry of Health have periodically considered mandatory generic prescribing rules that would require physicians to prescribe by International Non-proprietary Name (INN) rather than brand name. Implementation of such a policy would fundamentally disrupt the Indian branded generic market, since physician prescribing by brand name is the foundation on which the entire commercial model rests.<\/p>\n\n\n\n

As of early 2026, full mandatory INN prescribing has not been implemented nationally, though several state-level health initiatives and public hospital systems have moved toward it. The trajectory suggests a gradual compression of physician prescription autonomy in public healthcare settings, with private practice likely to retain brand-name prescribing for longer. This creates a two-speed market dynamic where branded generic premiums in private settings remain durable while public sector volume migrates toward INN generics.<\/p>\n\n\n\n

European Reference Pricing and Its Global Implications<\/h3>\n\n\n\n

Several emerging markets use European drug prices as reference points for domestic price negotiations. When branded generics successfully negotiate above-generic pricing in European markets, those prices cascade into reference pricing formulas in Southeast Asia and Latin America. Conversely, when European regulators negotiate price reductions for branded products, the cascading effect can reduce pricing power across multiple markets simultaneously.<\/p>\n\n\n\n

Companies managing global branded generic portfolios therefore cannot treat each market as fully independent. A price concession made to resolve a market access issue in Germany or France has potential implications for reference-pricing markets in Southeast Asia and Latin America. This interconnectedness makes global pricing governance a material strategic function for large branded generic companies, not merely an operational detail.<\/p>\n\n\n\n

Key Takeaways<\/h2>\n\n\n\n

Branded generics maintain 20%+ operating margins through five reinforcing mechanisms: brand equity that functions as a pricing floor, formulation differentiation backed by secondary IP, distribution infrastructure that is expensive to replicate, manufacturing scale advantages that compress cost of goods, and regulatory timing advantages that extend effective exclusivity.<\/p>\n\n\n\n

The margin durability varies significantly by geography. Emerging markets with fragmented retail pharmacy, limited payer consolidation, and strong physician prescribing culture (India, Southeast Asia, Latin America ex-Brazil, sub-Saharan Africa) provide the most favorable structural environments. Markets with mandatory generic substitution, centralized procurement, or sophisticated payer formulary management compress premiums substantially.<\/p>\n\n\n\n

Patent analysis is the starting point for any competitive assessment of a branded generic business, but the full IP stack matters more than the primary patent alone. Formulation patents, data exclusivity periods, and regulatory registration timing together create effective exclusivity periods that can be substantially longer than the primary patent expiry suggests. DrugPatentWatch and equivalent databases for non-US markets provide the raw material for this analysis.<\/p>\n\n\n\n

The China VBP experience is the case study that should inform every branded generic company’s scenario planning. Government-mandated volume-based procurement with centralized price-setting has the capacity to eliminate branded generic price premiums entirely within a single tender cycle, regardless of the depth of physician loyalty or brand equity built over decades.<\/p>\n\n\n\n

Quality system investment is a commercial cost as much as a compliance cost. The trust premium that supports branded generic pricing is among the most valuable and fragile of competitive assets. Quality failures destroy it rapidly; rebuilding it is slow and expensive.<\/p>\n\n\n\n

From an investor perspective, branded generic cash flows should be modeled with graduated price erosion assumptions over seven to ten years, not as a cliff event. Companies that execute formulation line extensions and combination products successfully can arrest the erosion curve, effectively resetting the commercial clock on specific products. The best branded generic managers are fundamentally portfolio managers of IP, brand equity, and product life cycles working simultaneously.<\/p>\n\n\n\n

FAQ<\/h2>\n\n\n\n

1. Why do some branded generics maintain price premiums for decades while others see premiums collapse within two years of generic entry?<\/h3>\n\n\n\n

The difference almost always comes down to two factors: whether the market has active generic substitution enforcement, and whether the branded generic company maintained physician relationships through the transition. In markets without mandatory substitution, physician prescription habits are sticky enough that a well-managed brand can sustain premiums for ten or more years. In markets with mandatory substitution, premiums collapse regardless of relationship quality. The second factor is investment: companies that continue detailing and educating physicians after patent expiry, at a reduced but sustained level, outperform those that cut commercial investment at the patent cliff.<\/p>\n\n\n\n

2. How do you use patent databases like DrugPatentWatch to assess the competitive position of a branded generic product?<\/h3>\n\n\n\n

Start with the primary patent expiry date, which tells you when the molecule becomes freely copyable. Then check for formulation patents listed in the Orange Book or equivalent registers, noting their expiry dates and any pending Paragraph IV challenges. Data exclusivity status is separate from patent status and can be queried independently. Count the number of ANDAs filed for the product, since that predicts competitive intensity after approval. Finally, check whether any ANDA applicant has received 180-day generic exclusivity, which creates a temporary two-player market immediately post-expiry. These five data points together give you a timeline model of when and how intensely generic competition will arrive.<\/p>\n\n\n\n

3. Is the branded generic business model ethical, or is it simply exploiting physician irrationality and patient information disadvantages?<\/h3>\n\n\n\n

The honest answer is: it depends on what the brand premium is actually funding. When the premium supports genuinely better manufacturing quality, consistent supply, pharmacovigilance infrastructure, and formulation improvements with real clinical value, the premium is defensible as payment for genuine differentiation. When it rests purely on physician habit, aggressive detailing of identical products, or regulatory barriers that delay competition without adding clinical value, the ethical position is weaker. The industry has examples of both. Payers and regulators who scrutinize branded generic pricing are typically responding to the second category, and their concerns are not without foundation.<\/p>\n\n\n\n

4. How should a generic company decide whether to pursue a branded generic strategy versus an unbranded commodity generic strategy?<\/h3>\n\n\n\n

The decision rests on target market selection, capital availability, and organizational capability. A branded generic strategy requires a sales force, brand investment, regulatory expertise, and a longer payback horizon than commodity generics but produces higher margins when it works. Commodity generic strategy requires manufacturing efficiency, regulatory pipeline management, and the ability to compete on price. The relevant question is whether your target markets have the structural conditions that support brand premiums: physician prescription culture, fragmented retail distribution, and limited payer-driven substitution. If those conditions are present and you have the capital to build the commercial infrastructure, branded generic returns are structurally superior. If those conditions are absent, chasing a brand premium in a commodity-priced market destroys value.<\/p>\n\n\n\n

5. What is the most common analytical mistake investors make when valuing branded generic businesses?<\/h3>\n\n\n\n

The most common error is using a single operating margin assumption across the full revenue forecast period without accounting for the graduated price erosion curve that occurs as generic competition intensifies. Investors often apply the current 25% operating margin to a five-year or ten-year revenue projection, which systematically overvalues companies in categories where two to four generics are already on the market or where regulatory changes are compressing price premiums. The second most common error is treating all markets within a company’s geographic footprint as having similar margin trajectories, when in practice margins in India, Latin America, Southeast Asia, and Europe compress at fundamentally different rates due to different regulatory and competitive environments.<\/p>\n\n\n\n

Pharmaceutical Business Intelligence | February 2026 | All data sourced from public filings, IQVIA market reports, DrugPatentWatch database, and published academic research<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

An investigative analysis of the business architecture behind pharma’s most durable profit model When Pfizer’s patent on atorvastatin expired in […]<\/p>\n","protected":false},"author":1,"featured_media":36666,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-36665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=36665"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36665\/revisions"}],"predecessor-version":[{"id":36667,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36665\/revisions\/36667"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/36666"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=36665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=36665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=36665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}